The era of generic weight loss drugs is approaching, and the first batch of patents for GLP drugs have expired, leading to a fierce competition among competitors
影殇·天问
发表于 2024-4-8 18:14:16
3798
0
0
The global weight loss drug market is currently divided into two parts. Novo Nordisk's Wegovy and Ozempic, as well as Eli Lilly's Zepbound and Mounjaro, are the most sought after and effective drugs in the market.
However, both companies are unable to provide drugs to more consumers due to production capacity issues. But this has also made the market for generic weight-loss drugs hot. The industry predicts that by 2030, the market size of GLP generic drugs will reach 100 billion US dollars.
The global patent for Saxenda, the injection of Liraglutide, the main component of Novo Nordisk's previous generation product, will expire in some countries this year. It is also one of the first GLP-1 drugs to lose patent protection. Last February, it had already lost patent protection in the Chinese market.
Compared to Wegovy and Ozempic, Saxenda is now somewhat like "tears of the times" (referring to outdated things), but its efficacy is not enough to make up for in quantity. The influx of generic drug companies will create a strong supply of generic drugs and lower prices, thereby expanding the market.
Among them, Biocon, a leading generic drug company in India, has obtained a license to replicate Saxenda in the UK. The CEO of the company, Siddharth Mittal, confidently stated that his team is ensuring Biocon's leading position in the generic pharmaceutical market. The company has also submitted applications to regulatory agencies in the United States and Europe to replicate the drug Liraglutide.
The future is bright
Weight loss pills have already created record breaking profits for Novo Nordisk and Lilly, which has caught the attention of other pharmaceutical companies, and generic drugs are the key way for them to openly compete for market share.
Biocon is a typical example of this. The company stated that it is building infrastructure to seize strategic opportunities centered around GLP drugs. Liraglutide products are just the beginning, waiting for the expiration of patents for more effective Smegglutide and Tezepamide products. The generic drug market is bound to ignite a greater wave of competition.
Mittal stated that weight loss drugs will be a very attractive market for the next 20 years, and the UK's approval of Biocon's production of generic Liraglutide demonstrates Biocon's ability to seize this opportunity.
There are also leaders in the Chinese market. Last year, the Liraglutide biosimilar developed by East China Pharmaceutical was approved for the treatment of obesity. Hangzhou Jiuyuan Genetic Engineering Co., Ltd. announced last week that it is applying to sell Megglutide generic drugs in China to control the blood sugar of patients with type 2 diabetes.
Jiuyuan Genetic Engineering also pointed out that it cannot commercialize drugs before the patent expires unless a court with jurisdiction determines that the patent is invalid. According to Novo Nordisk's annual report, the patent for its semaglutide drug in China will expire in 2026, while the patent for the European and American markets will expire from 2031 to 2032.
Jiuyuan Gene Factory also emphasized that the Chinese market potential of Smegglutide is enormous, with its scale increasing from 2.5 billion RMB in 2022 to 43.9 billion RMB in 2032, with a compound annual growth rate of up to 33%.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- The Federal Reserve's "Eagle Mouth" still exists! Speech by the first batch of officials after the resolution: Whether interest rates can be reduced depends on a few more data points
- Eisai/Bojian Alzheimer's disease drug rejected by the European Union, and Eli Lilly monoclonal antibody may be affected
- Digital Intelligence Morning Attendance | Nvidia released the humanoid robot training platform, and ByteDance became the first batch of enterprises to join
- AstraZeneca's market value has surpassed £ 200 billion for the first time! The bold bet on anti-cancer drugs is yielding results
- The US government announces the results of the first batch of "drug procurement" negotiations. Gaza ceasefire talks are highly divided. Global market
- Bristol Myers Squibb's original tumor treatment drug Abraxane has been officially launched in China
- The first batch of Apple 16 ProMax is not available in seconds! The trend of idle fish transfer is rising, and sellers are raising prices by 400-1000 yuan
- OpenAI announces receipt of Nvidia's first batch of DGX B200 engineering machines
- He Xiaopeng: Xiaopeng P7+'s first batch of production vehicles officially rolled off the production line
- TSMC reportedly receives the first batch of high NA EUV lithography machines from ASML before the end of the year
-
2024年11月7日,由新华社新闻信息中心、新华社上海分社、新华社品牌工作办公室主办的“品牌·让世界更美好”中外品牌论坛在上海举办。此次论坛,理想汽车荣获“通用ESG企业评价规范”年度最佳品牌奖。理想汽车将 ...
- cool88817
- 4 小时前
- 支持
- 反对
- 回复
- 收藏
-
【别跟我提特朗普!鲍威尔发布会:无需过度解读措辞改变 民众“不觉得经济好”没错】北京时间周五凌晨3点30分,美联储主席鲍威尔举行新闻发布会,就继续降息25个基点的决定和市场热点话题回答全球媒体提问。鲍威尔在 ...
- anhao007
- 半小时前
- 支持
- 反对
- 回复
- 收藏
-
何思文表示,“在进博会这个平台上,我们开启的是倾听模式,通过进博会展出各类产品,收集消费者的需求和反馈,进而帮助决定未来进口到中国的产品。过去,汽车行业的许多创新源于美国加州或欧洲。我相信,中国正 ...
- MaxLucky
- 10 小时前
- 支持
- 反对
- 回复
- 收藏
-
11月5日至10日,第七届中国国际进口博览会(下称“进博会”)在国家会展中心(上海)举办。在进博会期间,平安健康医疗科技有限公司(下称“平安健康”)与美敦力(上海)管理有限公司(下称“美敦力”)达成战 ...
- Hidden2
- 前天 17:06
- 支持
- 反对
- 回复
- 收藏